BNP Paribas Arbitrage SNC Has $17.88 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

BNP Paribas Arbitrage SNC boosted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) by 56.4% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 89,350 shares of the biopharmaceutical company’s stock after buying an additional 32,229 shares during the period. BNP Paribas Arbitrage SNC’s holdings in Alnylam Pharmaceuticals were worth $17,884,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the stock. Neuberger Berman Group LLC lifted its holdings in Alnylam Pharmaceuticals by 2.6% during the 3rd quarter. Neuberger Berman Group LLC now owns 4,818 shares of the biopharmaceutical company’s stock worth $965,000 after purchasing an additional 123 shares during the last quarter. Public Employees Retirement System of Ohio raised its position in shares of Alnylam Pharmaceuticals by 0.4% in the third quarter. Public Employees Retirement System of Ohio now owns 61,392 shares of the biopharmaceutical company’s stock valued at $12,288,000 after buying an additional 244 shares in the last quarter. Tang Capital Management LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at approximately $20,016,000. Two Sigma Advisers LP raised its position in shares of Alnylam Pharmaceuticals by 414.5% in the third quarter. Two Sigma Advisers LP now owns 63,800 shares of the biopharmaceutical company’s stock valued at $12,770,000 after buying an additional 51,400 shares in the last quarter. Finally, Two Sigma Investments LP acquired a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at approximately $43,377,000.

Insider Activity at Alnylam Pharmaceuticals

In related news, EVP Indrani Lall Franchini sold 1,675 shares of the business’s stock in a transaction on Thursday, February 2nd. The shares were sold at an average price of $226.01, for a total value of $378,566.75. Following the transaction, the executive vice president now owns 3,500 shares in the company, valued at $791,035. The transaction was disclosed in a document filed with the SEC, which is available through this link. In related news, EVP Indrani Lall Franchini sold 1,675 shares of the business’s stock in a transaction on Thursday, February 2nd. The shares were sold at an average price of $226.01, for a total value of $378,566.75. Following the transaction, the executive vice president now owns 3,500 shares in the company, valued at $791,035. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CMO Pushkal Garg sold 18,072 shares of the business’s stock in a transaction on Friday, March 3rd. The shares were sold at an average price of $200.00, for a total transaction of $3,614,400.00. Following the completion of the transaction, the chief marketing officer now owns 4,345 shares in the company, valued at approximately $869,000. The disclosure for this sale can be found here. 1.40% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on ALNY shares. Morgan Stanley decreased their price objective on shares of Alnylam Pharmaceuticals from $210.00 to $205.00 and set an “equal weight” rating on the stock in a research note on Friday, February 24th. Piper Sandler boosted their target price on shares of Alnylam Pharmaceuticals from $226.00 to $253.00 and gave the stock an “overweight” rating in a research note on Friday, December 16th. Citigroup decreased their target price on shares of Alnylam Pharmaceuticals from $270.00 to $265.00 and set a “buy” rating on the stock in a research note on Friday, February 24th. Oppenheimer decreased their target price on shares of Alnylam Pharmaceuticals from $256.00 to $249.00 and set an “outperform” rating on the stock in a research note on Friday, February 24th. Finally, SVB Leerink decreased their target price on shares of Alnylam Pharmaceuticals from $144.00 to $143.00 and set a “market perform” rating on the stock in a research note on Monday, January 23rd. Seven investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $244.26.

Alnylam Pharmaceuticals Stock Performance

Shares of Alnylam Pharmaceuticals stock opened at $187.10 on Wednesday. The company has a debt-to-equity ratio of 3.85, a current ratio of 3.51 and a quick ratio of 3.34. Alnylam Pharmaceuticals, Inc. has a twelve month low of $117.58 and a twelve month high of $242.97. The company’s fifty day moving average is $216.48 and its 200 day moving average is $213.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) last released its earnings results on Thursday, February 23rd. The biopharmaceutical company reported ($1.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.13) by $0.45. The business had revenue of $335.04 million for the quarter, compared to analyst estimates of $312.45 million. Alnylam Pharmaceuticals had a negative net margin of 109.04% and a negative return on equity of 1,287.80%. Alnylam Pharmaceuticals’s revenue for the quarter was up 29.6% on a year-over-year basis. During the same quarter in the previous year, the business earned ($2.16) earnings per share. On average, sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

About Alnylam Pharmaceuticals

(Get Rating)

Alnylam Pharmaceuticals, Inc is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R.